Country,NCT ID,Overall Status,Lead Sponsor,Start Date,End Date,Study Type,Phases,Interventions,Conditions,Enrollment
Laos,NCT00938379,UNKNOWN,London School of Hygiene and Tropical Medicine,2009-07,2011-06,INTERVENTIONAL,PHASE3,"20% deet insect repellent, placebo control","Malaria, Dengue, Japanese Encephalitis",5000
Laos,NCT04285021,COMPLETED,"Medecins Sans Frontieres, Spain",2020-03-05,2022-11-30,OBSERVATIONAL,Not Available,No interventions listed,Sepsis,3433
Laos,NCT05648448,RECRUITING,University of Oxford,2023-02-22,2027-01-01,INTERVENTIONAL,PHASE2,"Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir","Influenza, Influenza, Human",3000
Laos,NCT06089668,RECRUITING,"AN2 Therapeutics, Inc",2023-11-01,2026-01,OBSERVATIONAL,Not Available,Observational Study,Melioidosis,200
Laos,NCT05041907,RECRUITING,University of Oxford,2021-09-30,2027-01,INTERVENTIONAL,PHASE2,"Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Monoclonal antibodies, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir/ritonavir, Nirmatrelvir",COVID-19,3800
Laos,NCT04629053,RECRUITING,University of Oxford,2022-06-21,2024-12-01,OBSERVATIONAL,Not Available,No interventions listed,Acute Febrile Illness,7200
Laos,NCT04416945,UNKNOWN,"University of California, San Francisco",2020-09-20,2021-11-01,INTERVENTIONAL,NA,"Household Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up","Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria",31443
